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Purpose: Metabolic syndrome and cardiovascular disease are strongly associated with 
obstructive sleep apnea syndrome (OSAS), which causes substantial changes to normal 
circadian physiological functions, including metabolic pathways. Because core clock genes 
are known to be modulated by sleep/vigilance cycles, we asked whether the expression 
level of mRNA coding for clock genes is altered in non-treated OSAS patients and if it can 
be corrected by standard continuous positive airway pressure (CPAP) treatment.
Methods: Peripheral blood was collected from male patients diagnosed with severe 
OSAS (apnea-hypopnea index ≥ 30/h) before and after treatment initiation. qPCR was 
used to measure mRNA levels of genes associated with the central circadian pacemaker 
including CLOCK, BMAL1, Cry1, Cry2, and three Period genes (Per 1, 2, 3) in peripheral 
blood mononuclear cells (PBMCs).
results: We found statistically significant differences for CLOCK (p-value  =  0.022) 
expression in PBMCs of OSAS patients which were not reverted by treatment with 
CPAP. We have also found a substantial decrease in the slow wave sleep (SWS) content 
in OSAS patients (p-value < 0.001) that, contrary to REM sleep, was not corrected by 
CPAP (p-value = 0.875).
conclusion: CPAP treatment does not correct substantial changes in expression of core 
clock genes in OSAS patients. Because CPAP treatment is also unable to normalize the 
SWS in these patients, it is likely that additional therapeutic interventions that increase 
SWS content and complement the benefits of CPAP are required to more effectively 
reduce the known increased cardiovascular risk associated with OSAS patients.
Keywords: obstructive sleep apnea syndrome, clock genes, continuous positive airway pressure, slow wave 
sleep, Metabolic syndrome, circadian rhythms
inTrODUcTiOn
The obstructive sleep apnea syndrome (OSAS) is a frequent sleep disorder that constitutes an inde-
pendent risk factor for the development of metabolic syndrome and cardiovascular disease (1). Most of 
the gene components of critical metabolic pathways and their regulators exhibit circadian variation at 
the mRNA and protein levels (2). They are regulated by core clock genes, which in turn are modulated 
TaBle 1 | Polysomnography characterization of healthy controls and obstructive sleep apnea syndrome patients, before continuous positive airway pressure treatment.
control group Patient group
N 7 13
1st Quartile Median Mean 3rd Quartile 1st Quartile Median Mean 3rd Quartile
Age (years) 35.50 40.00 44.57 54.50 46.00 51.00 49.46 54.00
Oxygen desaturation index 0.10 0.30 1.16 1.60 40.60 59.70 57.92 71.40
Time spent with SpO2 < 90%, (min) 0.00 0.00 0.21 0.00 17.80 84.40 103.10 146.00
Lowest SpO2 (%) 91.25 92.50 91.50 93.00 68.00 75.00 72.69 78.00
Mean SpO2 (%) 96.00 96.00 96.00 96.00 91.00 91.00 91.23 93.00
ESS 0.00 2.00 2.60 3.00 9.00 12.00 11.45 15.00
Sleep efficiency (%) 76.70 90.00 84.69 94.30 72.72 82.60 80.34 88.92
Total sleep time (min) 366.40 377.20 368.70 389.20 295.80 353.20 350.00 399.50
REM (min) 40.12 60.25 58.48 76.62 3.65 8.45 9.40 15.62
Slow wave sleep (min) 53.50 58.25 58.75 75.38 0.00 1.55 3.86 4.63
Arousal index (events/h) 2.70 7.20 5.32 7.20 37.25 55.05 57.52 72.35
Apnea-hypopnea index (events/h) 0.85 1.50 2.00 3.05 41.50 67.10 61.88 78.40
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by sleep/vigilance cycles (3). Importantly, single genetic disruption 
of the core clock genes CLOCK (4) and BMAL1 (5, 6) cause full-
blown metabolic syndrome phenotypes in mice. Milder metabolic 
syndrome phenotypes have also been observed in double or triple, 
but not single, inactivation of additional core clock genes, includ-
ing Per1, 2, 3, and Cry1 and 2 (7). In this work, we investigated 
whether the expression level of mRNA coding for clock genes is 
altered in non-treated OSAS patients and if it can be corrected by 
continuous positive airway pressure (CPAP) treatment.
MaTerials anD MeThODs
study Population
Using polysomnography (Alice 5, Respironics, Inc., Murrysville, 
PA, USA) scored according to the 2007 AASM manual for the 
scoring of sleep and associated events and stringent clinical 
criteria (patients with addiction habits, cancer, hematological 
disorders, active infection, or shift work were excluded), we have 
identified a group of 13 male patients with severe OSAS [aver-
age apnea-hypopnea index (AHI) of 66.7/h, all ≥  30/h] and 7 
matched controls for sex (average AHI of 2, all < 5/h). Patients 
and controls, without the exclusion criteria, were recruited at the 
sleep consultation of Santa Maria Hospital (Lisbon, Portugal), 
from those with a high degree of suspicion to have Sleep Apnea, 
based on their clinical history. Patients and controls were distin-
guished on the basis of the PSG results. Sleepiness was evaluated 
using the Stanford Sleepiness Scale and the Epworth Sleepiness 
Scale (ESS). See Table  1 for sleep study results in the healthy 
and OSAS group. Cortisol levels were within normal limits for 
all subjects (data not shown). For a subset of patients, PSG was 
repeated after treatment with CPAP to assess its impact on REM 
and slow wave sleep (SWS) content. This study was approved by 
the Ethics Committee Review Board of Centro Hospitalar Lisboa 
Norte, EPE (Lisboa, Portugal), and written consent obtained for 
every patient and control sample included in this study.
Measurement of gene expression
We have used quantitative RT-PCR to systematically quantify 
the expression of the core clock genes in peripheral blood cells of 
severe OSAS patients in comparison with that of matched non-
affected control volunteers, before and after 1 month of treatment 
with CPAP. Several studies have demonstrated that clock gene 
expression profiles in human peripheral blood mononuclear cells 
(PBMCs) can be used as surrogate measures of central circadian 
rhythm expression changes in patients and healthy subjects (8–11). 
Therefore, peripheral blood was collected from the study subjects 
before and after 1 month of treatment initiation. Collections were 
always performed between 8 and 10 a.m. Blood was then used to 
perform routine biochemical analyses (including cortisol levels) 
and to isolate PBMCs. The following hematologic and biochemi-
cal parameters were investigated in all participants: full peripheral 
blood cell count; hepatic enzymes (aspartate transaminase, alanine 
transaminase, and gamma-glutamyltransferase); renal parameters 
(creatinine, blood urea nitrogen); standard metabolic parameters 
(uric acid, glucose, total cholesterol, low density lipoprotein, high 
density lipoprotein, triglycerides, and C-reactive protein). RNA 
was isolated and quantitative RT-PCR used to measure mRNA 
levels of genes associated with the central circadian pacemaker 
including CLOCK, BMAL1, two Cry (Cry 1, 2), and three Period 
genes (Per 1, 2, 3). The selected patients were then evaluated 
1 month after therapy initiation with CPAP and the mRNA level of 
the same genes tested. The sequence of the oligos used for RT-PCR 
can be found Table S2 in the Supplementary Material.
statistical analysis
A non-parametric approach was chosen for the data analysis. We 
used median and quartiles for the descriptive statistical analysis. 
To test hypotheses related to differences between the control 
group and the patient group, we used the Wilcoxon signed-rank 
test. To investigate relationships between gene expression and 
other parameters, we implemented a correlation analysis based 
on Spearman’s rank correlation coefficient.
resUlTs
Using Wilcoxon signed-rank test, we found statistically significant 
differences between patients and control volunteers in the ESS 
(W = 51.5, p-value = 0.007) and in polysomnography parameters 
TaBle 2 | Characterization of the gene expression between the control group (C) and the patient group at t1 (Pt1), as well as the results of hypothesis tests for 
comparison of gene expression between these groups.
Min 1st Quartile Median 3rd Quartile Max Mean sD hypothesis test
BMAL1 Pt1 0.54 0.72 0.81 1.27 5.01 1.26 1.22 W = 20, p-value = 0.068
C 0.91 1.09 1.38 1.95 2.27 1.52 0.54
CLOCK Pt1 0.16 0.42 0.99 1.32 2.53 1.03 0.69 W = 15, p-value = 0.022
C 1.18 1.29 2.20 2.31 3.72 2.04 0.90
CRY1 Pt1 0.96 1.18 1.52 2.12 2.85 1.68 0.65 W = 22, p-value = 0.230
C 1.26 1.58 2.13 2.57 3.31 2.14 0.73
CRY2 Pt1 0.19 1.30 1.53 1.95 3.08 1.58 0.79 W = 41, p-value = 0.601
C 0.82 1.01 1.33 1.81 1.97 1.39 0.47
PER1 Pt1 0.05 0.32 0.40 0.59 0.98 0.48 0.29 W = 27, p-value = 0.591
C 0.26 0.37 0.61 0.80 0.85 0.58 0.25
PER2 Pt1 0.83 1.58 2.61 2.88 3.51 2.35 0.88 W = 35, p-value = 0.438
C 2.06 2.26 2.52 3.98 6.20 3.32 1.63
PER3 Pt1 1.20 2.45 2.83 4.42 11.46 4.52 3.70 W = 53, p-value = 0.088
C 1.77 2.22 2.27 2.59 3.74 2.48 0.62
Only the CLOCK gene showed statistically significant changes.
TaBle 3 | Characterization of the gene expression within the patient group between the values recorded at t1 (Pt1) and the ones recorded at t2 (Pt2), as well as the 
results of hypothesis tests for comparison of gene expression between these time-points.
Min 1st Quartile Median 3rd Quartile Max Mean sD hypothesis test
BMAL1 Pt1 0.54 0.72 0.81 1.27 5.01 1.26 1.22 W = 57, p-value = 0.872
Pt2 0.21 0.87 1.13 1.28 1.65 1.03 0.45
CLOCK Pt1 0.16 0.42 0.99 1.32 2.53 1.03 0.69 W = 58, p-value = 0.923
Pt2 0.14 0.87 0.98 1.20 1.95 1.07 0.54
CRY1 Pt1 0.96 1.18 1.52 2.12 2.85 1.68 0.65 W = 32, p-value = 0.813
Pt2 0.85 1.20 1.55 2.38 3.86 1.92 1.06
CRY2 Pt1 0.19 1.30 1.53 1.95 3.08 1.58 0.79 W = 36, p-value = 0.756
Pt2 0.87 1.23 1.46 2.65 4.03 2.04 1.29
PER1 Pt1 0.05 0.32 0.40 0.59 0.98 0.48 0.29 W = 50, p-value = 1.000
Pt2 0.21 0.37 0.39 0.50 0.74 0.43 0.17
PER2 Pt1 0.83 1.58 2.61 2.88 3.51 2.35 0.88 W = 65, p-value = 0.733
Pt2 1.07 2.24 2.74 2.79 5.42 2.70 1.11
PER3 Pt1 1.20 2.45 2.83 4.42 11.46 4.52 3.70 W = 27, p-value = 0.475
Pt2 2.42 2.94 4.36 4.96 8.44 4.43 2.07
These comparisons did not reveal any significant differences.
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(Table 1) including in AHI (W = 91, p-value < 0.0001), oxygen 
desaturation index (W = 91, p-value < 0.001), SpO2 time < 90% 
in minutes (W = 90, p-value < 0.001), minimal SpO2 (W = 1, 
p-value < 0.0001), and average SpO2 (W = 1.5, p-value < 0.001). 
Statistically significant differences were also found for SWS in 
minutes (W = 0, p-value < 0.001), REM sleep in minutes (W = 0, 
p-value = 0.0001), and arousal index (W = 60, p-value < 0.002), 
but not for sleep efficiency (W = 29.5, p-value = 0.310) or total 
sleep time (W = 34, p-value = 0.892).
On the comparison between control volunteers and patients 
before treatment initiation, we found statistically significant 
differences for CLOCK (W = 15, p-value = 0.022) expression in 
PBMCs of patients, but not for Cry 1 and 2 or the three Period 
genes tested (Table  2). The differences of BMAL1 expression 
between control volunteers and patients nearly reached statistical 
significance (W = 20, p-value = 0.068), an outcome that is likely, 
should the population size be larger.
Patient treatment with CPAP did not change abnormal 
expression of clock genes (Table 3). It also did not improve the 
reduced levels of SWS observed in non-treated OSAS patients 
(p-value = 0.875, Table 4), contrary to REM sleep. The persistence 
of the abnormal expression pattern of the CLOCK gene cannot be 
attributed to the lack or sub-optimal adherence levels to CPAP 
treatment as demonstrated by the metrics of CPAP adherence 
of our patients (Table  5; Table S1 in Supplementary Material). 
Our data show that adherence to CPAP treatment is well above 
the minimum required level recommended by the most recent 
proposal of the American Thoracic Society (12) that points to the 
need of CPAP use in more than 70% of nights and for more than 
4 h per night.
DiscUssiOn
In our study, as expected, control volunteers and OSAS patients 
could be easily distinguished by the statistical analysis of the ESS 
results and polysomnography parameters. They could also be 
distinguished on the basis of expression levels of CLOCK, but not 
any of the other core clock genes, with the possible exception of 
TaBle 5 | Statistical Characterization of the continuous positive airway pressure 
adherence.
Min 1st 
Quartile
Median Mean 3rd 
Quartile
Max
Days of use (%) 76 86.8 96.8 93.1 100.0 100.0
Average number 
of hours of use 
per day (h)
1.1 3.35 5.42 4.97 6.60 7.37
IAH flow 0.5 1.15 1.95 3.07 3.55 10.40
IA flow 0.3 0.45 0.70 1.43 1.68 6.70
TaBle 4 | Slow wave sleep (SWS) and REM content, shown in percentage 
(%), in controls and patients (at diagnosis and after continuous positive airway 
pressure treatment).
Patients controls
no treatment Treatment
reM sWs reM sWs reM sWs
Min 0.00 0.00 9.60 1.40 9.50 3.80
1st Q 3.68 2.25 12.53 3.28 12.05 10.20
Median 6.70 4.45 15.30 4.35 15.90 15.60
Mean 7.85 5.48 16.85 4.95 15.53 14.86
3rd Q 10.88 7.68 19.62 6.03 17.95 20.00
Max 18.00 13.00 27.20 9.70 23.30 24.20
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BMAL1. Interestingly, these results are strikingly reminiscent of 
metabolic syndrome phenotypes found in the knockout of the 
corresponding genes in mice as described earlier. The levels of 
expression of the CLOCK gene were altered in OSAS patients 
before and after CPAP treatment, suggesting that either the 
standard therapeutic management of these patients is insufficient 
to correct the disruption of the circadian patterns of genes with 
expression conditioned by cycles of sleep/vigilance or changes 
in severe sleep apnea patients are structural, for example, as a 
consequence of irreversible cerebral vascular lesions.
Before patients were treated, we observed consistently and sub-
stantially reduced levels of REM and SWS content as compared to 
healthy controls. Perhaps significantly, while all the patients who 
initiated CPAP recovered to normal levels of REM sleep, SWS 
content remained invariably abnormal, at much lower levels than 
controls (Table 4). It was previously shown that even in young 
healthy adults, selective suppression of SWS causes pronounced 
decrease of insulin sensitivity, reduced glucose tolerance, and 
higher diabetes risk (13).
While it is clear that CPAP substantially improves cognitive 
and behavioral aspects of the disease (14), metabolic parameters 
and other OSAS-related risk factors are only partially modified 
(15), which might explain the incomplete reduction of cardiovas-
cular risk in OSAS. These facts point to the need to complement 
CPAP therapy with other therapy interventions that are aimed 
at the sleep structure and circadian rhythm normalization and 
are likely to have a substantial impact on the natural history of 
the disease. Drugs that effectively improve the SWS content of 
patients might constitute prime candidates for this goal.
study limitations
While our major conclusions are supported by robust statistically 
significant results, our study would benefit from increasing the 
size of the population of both patients and controls. It is likely that 
with more samples, statistically significant associations will be 
found for additional clock genes, especially in the case of BMAL1, 
where a trend is already clear with the current analysis.
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